← Leaderboards
Levi Alexander Garraway
Dana-Farber Cancer Institute
$17,056,330
Attributed
$21,717,781
Total exposure
14
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2005–17$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$21,717,781 · 14
By mechanism
U01$5,861,114 · 2
P01$2,930,230 · 1
U10$2,722,758 · 1
DP2$2,565,000 · 1
P50$2,437,406 · 3
R35$1,462,833 · 1
Top collaborators
- Clara D Bloomfield4 shared
- Pasi A Janne4 shared
- Guido Marcucci4 shared
- Jerald P Radich4 shared
- Laura E Macconaill3 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Stuart K Calderwood$11,938,045
- Jyoti Sen$245,497
- Wen-Shu Wu$5,750,738
- Thomas S. Kupper$36,607,647
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorBaseGeneticGenomicsMutationMalignant NeoplasmsMolecularOncogenesResistanceTechnologyPathway InteractionsTherapeutic TargetDesignInsightOncologyMedicalInstitutesClinical TrialsGenomeCellsResponseTissuesMelanomaSignal Transduction
Grant awards (49)
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie$643,941
U10 · FY2017 · CA
Defining and Modeling Resistance to RAF/MEK Inhibition in Human Melanoma$388,654
P01 · FY2017 · CA · contact PI
Genomic Determinants of Resistance to Primary Androgen Deprivation Therapy and A$260,826
P50 · FY2017 · CA · contact PI
Overcoming Resistance to RAF Inhibition in BRAF-Mutant Colorectal Cancer$254,973
P50 · FY2017 · CA · contact PI
Overcoming resistance to targeted therapy in cancer$831,341
R35 · FY2016 · CA · contact PI
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie$687,345
U10 · FY2016 · CA
Defining and Modeling Resistance to RAF/MEK Inhibition in Human Melanoma$627,899
P01 · FY2016 · CA · contact PI
Genomic Determinants of Resistance to Primary Androgen Deprivation Therapy and A$241,043
P50 · FY2016 · CA · contact PI
Overcoming Resistance to RAF Inhibition in BRAF-Mutant Colorectal Cancer$239,907
P50 · FY2016 · CA · contact PI
Overcoming resistance to targeted therapy in cancer$86,961
R35 · FY2016 · CA · contact PI
Overcoming resistance to targeted therapy in cancer$71,059
R35 · FY2016 · CA · contact PI
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie$691,472
U10 · FY2015 · CA
Defining and Modeling Resistance to RAF/MEK Inhibition in Human Melanoma$625,649
P01 · FY2015 · CA · contact PI
Overcoming resistance to targeted therapy in cancer$473,472
R35 · FY2015 · CA · contact PI
Systematic Genetic Characterization of African American Prostate Cancer$336,840
U01 · FY2015 · CA · contact PI
Overcoming Resistance to RAF Inhibition in BRAF-Mutant Colorectal Cancer$247,329
P50 · FY2015 · CA · contact PI
Genomic Determinants of Resistance to Primary Androgen Deprivation Therapy and A$242,400
P50 · FY2015 · CA · contact PI
The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients$73,267
U01 · FY2015 · HG · contact PI
The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients$1,470,233
U01 · FY2014 · HG · contact PI
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie$700,000
U10 · FY2014 · CA
Defining and Modeling Resistance to RAF/MEK Inhibition in Human Melanoma$606,879
P01 · FY2014 · CA · contact PI
Systematic Genetic Characterization of African American Prostate Cancer$331,631
U01 · FY2014 · CA · contact PI
Overcoming Resistance to RAF Inhibition in BRAF-Mutant Colorectal Cancer$239,495
P50 · FY2014 · CA · contact PI
Genomic Determinants of Resistance to Primary Androgen Deprivation Therapy and A$231,682
P50 · FY2014 · CA · contact PI
The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients$1,449,598
U01 · FY2013 · HG · contact PI
Defining and Modeling Resistance to RAF/MEK Inhibition in Human Melanoma$681,149
P01 · FY2013 · CA · contact PI
Systematic Genetic Characterization of African American Prostate Cancer$324,265
U01 · FY2013 · CA · contact PI
Genomic Determinants of Resistance to Primary Androgen Deprivation Therapy and A$242,244
P50 · FY2013 · CA · contact PI
Overcoming Resistance to RAF Inhibition in BRAF-Mutant Colorectal Cancer$237,507
P50 · FY2013 · CA · contact PI
High-Throughput Tumor Genomic Profiling by Massively Parallel Sequencing$228,692
R33 · FY2013 · CA · contact PI
The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients$1,528,530
U01 · FY2012 · HG · contact PI
Systematic Genetic Characterization of African American Prostate Cancer$346,750
U01 · FY2012 · CA · contact PI
High-Throughput Tumor Genomic Profiling by Massively Parallel Sequencing$263,445
R33 · FY2012 · CA · contact PI
High-throughput oncogene mutation detection in human cancer$315,153
R33 · FY2011 · CA · contact PI
High-Throughput Tumor Genomic Profiling by Massively Parallel Sequencing$225,000
R33 · FY2011 · CA · contact PI
High-throughput oncogene mutation detection in human cancer$292,410
R33 · FY2010 · CA · contact PI
Functional Analysis of the PTEN Tumor Suppressor Protein$265,975
R01 · FY2009 · CA · contact PI
Integrated Functional Genomic Analyses of Melanoma$136,890
K08 · FY2009 · CA · contact PI
Functional Analysis of the PTEN Tumor Suppressor Protein$266,257
R01 · FY2008 · CA · contact PI
High-throughput oncogene mutation detection in human cancer$205,200
R21 · FY2008 · CA · contact PI
Integrated Functional Genomic Analyses of Melanoma$136,890
K08 · FY2008 · CA · contact PI
Defining Melanoma Therapeutic Avenues by Integrative Functional Genomics$2,565,000
DP2 · FY2007 · OD · contact PI
Functional Analysis of the PTEN Tumor Suppressor Protein$266,531
R01 · FY2007 · CA · contact PI
High-throughput oncogene mutation detection in human cancer$171,000
R21 · FY2007 · CA · contact PI
Integrated Functional Genomic Analyses of Melanoma$136,890
K08 · FY2007 · CA · contact PI
Functional Analysis of the PTEN Tumor Suppressor Protein$274,252
R01 · FY2006 · CA · contact PI
Integrated Functional Genomic Analyses of Melanoma$136,890
K08 · FY2006 · CA · contact PI
Functional Analysis of the PTEN Tumor Suppressor Protein$280,075
R01 · FY2005 · CA
Integrated Functional Genomic Analyses of Melanoma$136,890
K08 · FY2005 · CA